Revenue
2019
2020
2022
2023
2024
2025
Silo Pharma, Inc. (SILO)
Price$2.32Cached quote
Net income
2011
2012
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72,102 | $72,102 | $72,102 | $72,102 | — | $40,923 | $40,569 | — | — | — | — | — |
| Gross profit | $27,807 | $66,264 | $66,264 | $66,264 | $66,260 | −$135,203 | $13,182 | — | — | — | — | — |
| Gross margin | 38.57% | 91.90% | 91.90% | 91.90% | — | −330.38% | 32.49% | — | — | — | — | — |
| Research & development | $2.2M | $2.4M | $845,092 | $1.3M | $693,910 | $26,250 | — | — | — | — | — | — |
| Operating expenses | $4.3M | $4.8M | $3.9M | $3.7M | $2.8M | $2.2M | $943,585 | $594,242 | $490,871 | — | — | — |
| Operating income | −$4.3M | −$4.7M | −$3.9M | −$3.6M | −$2.7M | −$2.2M | −$930,403 | −$594,242 | −$490,871 | — | — | — |
| Operating margin | −5,936.95% | −6,526.44% | −5,347.41% | −5,031.28% | — | −5,380.15% | −2,293.38% | — | — | — | — | — |
| EBITDA | −$4.2M | −$4.4M | −$3.6M | −$3.9M | — | — | — | — | — | — | — | — |
| EBITDA margin | −5,795.89% | −6,076.96% | −5,029.28% | −5,416.20% | — | — | — | — | — | — | — | — |
| Net income | −$4.2M | −$4.4M | −$3.7M | −$3.9M | $3.9M | −$3.0M | −$1.0M | −$969,463 | $356,536 | — | −$39,446 | −$49,803 |
| Net profit margin | −5,863.50% | −6,092.59% | −5,132.57% | −5,420.86% | — | −7,422.52% | −2,497.71% | — | — | — | — | — |
| Basic EPSper basic share | -$7.50 | -$17.85 | -$18.00 | -$25.65 | $30.00 | -$37.50 | -$30.00 | -$15.00 | $7.50 | — | $0.00 | $0.00 |
| Diluted EPSper diluted share | -$7.50 | -$17.85 | -$18.00 | -$25.65 | $30.00 | -$37.50 | -$30.00 | -$15.00 | $7.50 | — | $0.00 | $0.00 |
Owners
Reported shareholders
≈19.22%of listed shares
Weisblum Eric216.93K shares · Dec 15, 2025
View holders
| Holder | % owned |
|---|---|
Weisblum Eric | ≈19.22%216.93K shares |
AdvisorShares Investments LLC | 6.70%75.58K shares |
FNY Investment Advisers, LLC | 3.32%37.51K shares |
CITADEL ADVISORS LLC | 1.49%16.8K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.06%11.96K shares |
VANGUARD FIDUCIARY TRUST CO | 0.08%874 shares |
Tower Research Capital LLC (TRC) | 0.02%181 shares |
HARBOUR INVESTMENTS, INC. | <0.01%14 shares |
CITIGROUP INC | <0.01%1 shares |
Percentages use 1.13M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 15, 2025Form 4 | Weisblum EricChief Executive Officer | BuyCommon Stock | 2.5K | $0.42 | $1.1K | 216.9K |
| Dec 15, 2025Form 4 | Weisblum EricChief Executive Officer | BuyCommon Stock | 2.5K | $0.41 | $1.0K | 214.4K |
| Nov 21, 2025Form 4 | Weisblum EricChief Executive Officer | BuyCommon Stock | 1.0K | $0.37 | $370.00 | 211.9K |
| Nov 20, 2025Form 4 | Weisblum EricChief Executive Officer | BuyCommon Stock | 1.0K | $0.37 | $370.00 | 210.9K |
| Nov 19, 2025Form 4 | Weisblum EricChief Executive Officer | BuyCommon Stock | 4.5K | $0.41 | $1.8K | 209.9K |